Pharmacokinetics and pharmacodynamics of CI-992 following intravenous and oral administration to cynomolgus monkeys

Cook, Jack; Burger, Paula; Michniewicz, Barbara M.; Nordblom, Gerald D.; Hicks, Gary W.; Kaplan, Charles D.; Ryan, Michael J.

doi:10.1002/(sici)1099-081x(199804)19:3<185::aid-bdd92>3.0.co;2-c

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

2010

Publication Types

Select...

Article2

Other1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 13 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Antihypertensives: Renin Inhibitors

Tice¹,

McGeehan²,

Claremon³

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Renin has been recognized as an attractive target for antihypertensive drugs since the 1950s. Intensive efforts in the 1980s focused on peptidomimetic hydroxy transition‐state isosteres led to many potent renin inhibitors. However, none of these compounds was developed as a drug. The advent of routine X‐ray crystallography of protein–ligand complexes provided additional insights that culminated in the discovery of aliskiren, a fully nonpeptidic renin inhibitor. Aliskiren, the first direct renin inhibitor to reach the market, was approved as an antihypertensive in 2007. Preliminary clinical trials suggest that aliskiren, and potentially other direct renin inhibitors, may have utility in end organ protection and congestive heart failure, in addition to hypertension.

show abstract